ELECSYS TOTAL PSA IMMUNOASSAY AND TOTAL PSA CALSET
Roche Diagnostics Corp. · Decision date Apr 29, 2026
What did the FDA decide?
FDA records P990056/S046 as a supplement to PMA P990056, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 29, 2026.
FDA approval order statement
manufacturing and testing improvements to the Elecsys Streptavidin (SA)-coated microparticles
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Apr 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P990056/S046
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Diagnostics Corp.
- Product code
- MTF
- Decision code
- OK30
- Decision date
- Apr 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.
- Applicant
- Roche Diagnostics Corp.
- Product code
- MTF
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P990056/S045 · Related supplement
Elecsys total PSA assay
P990056/S046 received
Application receipt date recorded by FDA.
P990056/S046 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P990056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Elecsys total PSA assayP990056/S045 | Roche Diagnostics Corp. | PMA supplement | Feb 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MTF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems PSAP930027/S041 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Atellica IM Total PSA II (tPSAII)P240021/S001 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 26, 2026 | FDA |
IMMULITE Systems PSAP930027/S040 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 PSAP930027/S039 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
IMMULITE 2000 PSAP930027/S038 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9115 Hague Rd., Indianapolis, IN, 46250
Sources and methodology
- Original FDA record: P990056/S046
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


